BiotechTube

Enzalutamide + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Castration-Resistant Prostate Cancer

Conditions

Castration-Resistant Prostate Cancer

Trial Timeline

Sep 30, 2009 → Nov 2, 2017

NCT ID
NCT00974311

About Enzalutamide + Placebo

Enzalutamide + Placebo is a phase 3 stage product being developed by Astellas Pharma for Castration-Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00974311. Target conditions include Castration-Resistant Prostate Cancer.

What happened to similar drugs?

4 of 20 similar drugs in Castration-Resistant Prostate Cancer were approved

Approved (4) Terminated (1) Active (15)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅olaparib + enzalutamide + abiraterone acetate + PrednisoneAstraZenecaApproved
✅Darolutamide (Nubeqa, BAY1841788)BayerApproved
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄[Lu-177]-PNT2002 + Abiraterone + EnzalutamideEli LillyPhase 3
🔄Fuzuloparib , Abiraterone acetate and Prednisone + Fuzuloparib Placebo， Abiraterone acetate and PrednisoneJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT02677896Phase 3Completed
NCT02528643Phase 2Completed
NCT02294461Phase 3Completed
NCT02003924Phase 3Completed
NCT01212991Phase 3Completed
NCT00974311Phase 3Completed

Competing Products

20 competing products in Castration-Resistant Prostate Cancer

See all competitors
ProductCompanyStageHype Score
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue MedicationDaiichi SankyoPhase 1/2
39
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
EnzalutamideAstellas PharmaPhase 2
35
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
Crizotinib + EnzalutamideAstellas PharmaPhase 1
29
EnzalutamideAstellas PharmaPhase 2
35
Lu-PSMA + EnzalutamideAstellas PharmaPhase 2
31
EnzalutamideAstellas PharmaApproved
43
enzalutamideAstellas PharmaPre-clinical
26
Enzalutamide + FlutamideAstellas PharmaPhase 2
35
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
26
EnzalutamideAstellas PharmaApproved
43
EnzalutamideAstellas PharmaPhase 2
35
MDV3100Astellas PharmaPre-clinical
26
ZEN003694 + EnzalutamideAstellas PharmaPhase 2
42
Enfortumab vedotinAstellas PharmaPhase 2
39
EnzalutamideAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + PlaceboAstellas PharmaPhase 3
40